NAMD

US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies

Retrieved on: 
Tuesday, March 19, 2024
Retina, Stargardt disease, Macular edema, Retinitis pigmentosa, Eye, Intelligence, Paratriathlon, Hope, Stargardt, Adverum Biotechnologies, Safety, NAMD, Geographic atrophy, Ophthalmology, Diabetic retinopathy, Medical device

Unlike other organs, the eye's compact size and accessibility have made it an ideal application for gene therapies, offering targeted treatment with minimal systemic impact.

Key Points: 
  • Unlike other organs, the eye's compact size and accessibility have made it an ideal application for gene therapies, offering targeted treatment with minimal systemic impact.
  • As advancements continue, a plethora of gene therapies for retinal disorders are on the horizon.
  • Spherix Global Insights collaborated with 77 retinal specialists to understand their perspectives on adopting gene therapies, specifically where specialists were and were not willing to use gene therapy across diseases and patient types.
  • While retinal specialists express eagerness for gene therapies, dissatisfaction towards current treatments like Syfovre and Izervay underscores the need for innovation.

Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024
Research, Biotechnology, Disease, Paratriathlon, Patient, Ageing, ARVO, Quality of life, Life expectancy, Retina, Bleeding, Pharmacokinetics, AMD, NAMD, Annual general meeting

Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals.

Key Points: 
  • Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals.
  • With the increase in life expectancy, the number of reported cases of AMD is increasing.
  • The disease and its current treatment regimen add significant burden on patients, caretakers, and on health care system.
  • nAMD accounts for roughly 10% of all AMD cases, but almost 90% of AMD-related central vision loss.

EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

Retrieved on: 
Wednesday, March 13, 2024
Diabetes, Paratriathlon, Eye, Blood, Retina, Biosimilar, Gulf Cooperation Council, GCC, Ranibizumab, Prevalence, DR, Health, VEGF, Macular degeneration, Patient, NAMD, DME, CBO, Visual impairment, Partnership, Pharmaceutical industry

In addition, further market launches are planned in Algeria and other Gulf Cooperation Council (GCC) markets over the course of 2024.

Key Points: 
  • In addition, further market launches are planned in Algeria and other Gulf Cooperation Council (GCC) markets over the course of 2024.
  • This strategic collaboration aims to improve access to ophthalmic treatments in the MENA region.
  • Biosimilar and specialty medicines are integral to MS Pharma product portfolio and play a crucial role in advancing our growth objectives in the MENA region.
  • This approval supports the company's commitment to the Saudi market and its broader strategic initiatives within the kingdom."

Nine States Selected for Children's Behavioral Health Policy Lab

Retrieved on: 
Wednesday, January 31, 2024
CBH, Partnership, Multimedia, Policy, COVID-19, APHSA, Casey Family Programs, Child, K-12, Health Management Associates, CWLA, NAMD, Justice, Investment, School, MITRE, Justice minister, Mental health, Trauma, Motion, HMA, National Association

LANSING, Mich., Jan. 31, 2024 /PRNewswire/ -- Health Management Associates (HMA), in partnership with the Annie E. Casey Foundation, Casey Family Programs, National Association of State Mental Health Program Directors (NASMHPD), the Child Welfare League of America (CWLA), the American Public Human Services Association (APHSA), National Association of Medicaid Directors (NAMD) and the Centene Foundation, will convene a Children's Behavioral Health (CBH) State Policy Lab, Feb. 7-9 in Baltimore. HMA today announced the selection of nine states – Georgia, Kansas, Kentucky, Maryland, Missouri, Pennsylvania, Texas, Utah, and Wisconsin – that will participate in the policy lab. MITRE, which previously hosted a related federal convening, will also take part in this state convening.

Key Points: 
  • HMA today announced the selection of nine states – Georgia, Kansas, Kentucky, Maryland, Missouri, Pennsylvania, Texas, Utah, and Wisconsin – that will participate in the policy lab.
  • COVID-19 has exacerbated long-standing system collaboration challenges across state child welfare, behavioral health, and Medicaid that lead to unsatisfactory outcomes for the most vulnerable children in our communities.
  • Most worrisome is the worsening of behavioral and physical health challenges and trauma because of uncoordinated or fragmented care.
  • In November, a call for applications was released to U.S. states and territories for potential participation in the State Policy Lab.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Manatt Strengthens Medicaid Offerings With Arrival of Trusted Director and Health System Executive

Retrieved on: 
Thursday, January 4, 2024
Legal, Consulting, Public Policy, Government, Healthcare Reform, Professional Services, Other Health, Managed Care, Health, Other Professional Services, Policy, University, Hospital, LLP, Denver Health Medical Center, National Association, CMMI, NAMD, Oak Ridge Associated Universities, Knowledge, Medicare, COVID-19, Interim, Population health, Safety, Manatt, Phelps & Phillips, Pharmaceutical industry

Johnson has advised clients on coverage policy, advanced primary care models, population health strategies, telehealth and value-based care in Medicaid.

Key Points: 
  • Johnson has advised clients on coverage policy, advanced primary care models, population health strategies, telehealth and value-based care in Medicaid.
  • Johnson also spent nine years at the Denver Health and Hospital Authority in multiple executive roles, including special assistant to the CEO, Director of Health Care Reform Initiatives and Interim Director of the Center for Population Health.
  • “I have always admired Manatt Health and absolutely relied on its thought leadership during my tenure as Medicaid Director and at CMMI.
  • I am thrilled to join the brilliant, committed and growing team of trusted advisers focused on state health policy.”

EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)

Retrieved on: 
Saturday, December 30, 2023
NAMD, Marketing, EMA, MAA, Retina, Blood, VEGF, Ageing, European Medicines Agency, Aflibercept, Ophthalmology, Vaccine

Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)

Key Points: 
  • Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
    The issuer is solely responsible for the content of this announcement.
  • Press Release // November 27, 2023
    Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
    Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (Klinge) announce that the marketing authorization application (MAA) for FYB203, a biosimilar candidate for Eylea®1 (Active ingredient: Aflibercept) has been submitted to the European Medicines Agency (EMA).
  • Eylea® is used in the treatment of neovascular age-related macular degeneration (nAMD) and other severe retinal diseases.
  • "Our latest MAA submission once again demonstrates the high performance and reliability of the entire #TeamFormycon.

EQS-News: Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®

Retrieved on: 
Saturday, December 30, 2023
NAMD, Quality of life, Partnership, Eye, Risk, Teva Canada, Retina, Paratriathlon, Blood, Visual impairment, AMD, VEGF, OECD, Genentech, Health Canada, Ranibizumab, NOC, Growth, Supervisory board, Patient, Generic drug

Press Release // December 07, 2023

Key Points: 
  • Press Release // December 07, 2023
    Munich, Amsterdam, Zug, Toronto – Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. jointly announce that Health Canada has granted the “Notice of Compliance” (NOC) for Ranopto®1 (Ranibizumab), a biosimilar to Lucentis®2, for the treatment of several serious retinal diseases in Canada.
  • Mid 2021, Teva Pharmaceutical Industries Ltd. (“Teva”) entered into a strategic partnership for the exclusive commercialization of FYB201 in Canada, Europe and selected other countries.
  • Commercial launch by Teva Canada Ltd. is expected to start in the first quarter of 2024.
  • “The approval in Canada underlines the excellent work we have done together with our partners in the development of FYB201/Ranopto®.

Opthea to Present at the FLORetina 2023 Congress

Retrieved on: 
Friday, December 1, 2023
NAMD, ASX, Retina, MD, Congress, Catholic higher education, Pharmaceutical industry

MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.

Key Points: 
  • MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.
  • Professor Angelo Maria Minnella, MD from the Department of Ophthalmology, Catholic University Sacro Cuore-Policlinico A. Gemelli, Rome, Italy, will present on the Company’s lead program, sozinibercept combination therapy in neovascular age-related macular degeneration (nAMD) in a session highlighting innovative therapies.
  • The annual FLORetina Congress is one of the largest retina meetings in Europe with over 2500 participants attending from over 50 countries.
  • The details for the podium presentation are as follows:

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

Retrieved on: 
Tuesday, December 5, 2023
Health, Communications, Clinical Trials, Pharmaceutical, Publishing, Optical, Biotechnology, Yoshi, Intravitreal injection, Safety, Visual acuity, Retina, Royal college, Anatomy, Risk, Exudate, Anti-VEGF, FGF2, Patient, P, Choroidal neovascularization, Aptamer, Eye, Therapy, Blood, Growth factor, Royal College of Ophthalmologists, Paratriathlon, NAMD, SUSHI, Fibrosis, Pharmaceutical industry, D.S

TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.

Key Points: 
  • TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.
  • Throughout these studies umedaptanib pegol was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment.
  • In nAMD patients with a long history of anti-VEGF treatment, umedaptanib pegol showed no additional benefit of monotherapy or the combination over Eylea®.
  • Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study.